Skip to main content

Teriparatide vs Epigen

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Teriparatide

Teriparatide (Forteo) is recombinant human parathyroid hormone (1-34), FDA-approved for osteoporosis treatment. It's unique among osteoporosis drugs in that it stimulates new bone formation.

Full details →

Epigen

Epigen is a member of the epidermal growth factor (EGF) family. It plays roles in skin regeneration and has been studied for wound healing and anti-aging applications.

Full details →

Side-by-Side Comparison

AspectTeriparatideEpigen
MechanismIntermittent PTH exposure paradoxically stimulates osteoblasts more than osteoclasts, resulting in net bone formation. Continuous exposure would cause bone loss, but pulsatile dosing builds bone.Binds to and activates the EGF receptor (EGFR), promoting cell proliferation, migration, and differentiation. Involved in skin homeostasis and repair processes.
Typical Dosage20mcg subcutaneously once daily. Maximum treatment duration of 2 years due to theoretical osteosarcoma risk from rat studies.Topical: Typically used at low concentrations (ppm to low %) in cosmetic formulations. Research applications vary.
AdministrationSubcutaneous injection in thigh or abdomen once daily. Delivered via multi-dose pen. Should sit or lie down after injection due to orthostatic hypotension risk.Primarily topical application for skincare. Research may use other routes for systemic effects.
Side EffectsOrthostatic hypotension, leg cramps, nausea, dizziness, headache, and injection site reactions. Transient hypercalcemia possible.Topical use generally well-tolerated. Theoretical concerns about promoting cell proliferation.
Best For

What They Have in Common

Both Teriparatide and Epigen are commonly used for:

Key Differences

Unique to Epigen:

Detailed Analysis

Both Epigen and Teriparatide are commonly used for Recovery & Healing.

Which Should You Choose?

Teriparatide has stronger evidence for Recovery & Healing.

Ready to Learn More?